GlassScriptPhysician profile
Junaid Munshi
NPI 1629411129
$3,393.18
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $654 · 2021: $501 · 2022: $1,360.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Murata Vios, INC. | $1,360.00 | 2022 | |
| Novo Nordisk INC | $519.66 | 2019-2021 | |
| Lilly USA, LLC | $407.00 | 2019-2021 | |
| Pfizer INC. | $196.06 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $156.95 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.01 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $98.26 | 2019-2021 | |
| Abbott Laboratories | $79.17 | 2019-2021 | |
| Glaxosmithkline, LLC. | $74.74 | 2019-2021 | |
| Amgen INC. | $72.64 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $55.35 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $33.68 | 2021 | |
| Abbvie INC. | $32.88 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.78 | 2019-2021 | |
| Astellas Pharma US INC | $24.64 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24.43 | 2020 | |
| Allergan, INC. | $24.19 | 2019-2020 | |
| Tris Pharma INC | $17.06 | 2019 | |
| Vyera Pharmaceuticals, LLC | $16.05 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.45 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.66 | 2021 | |
| Sanofi Pasteur INC. | $14.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.75 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junaid Munshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.